S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
66,000% upside on tiny biotech? (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
66,000% upside on tiny biotech? (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
66,000% upside on tiny biotech? (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
66,000% upside on tiny biotech? (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
NASDAQ:FIXX

Homology Medicines (FIXX) Stock Forecast, Price & News

$0.98
-0.01 (-1.01%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.98
$1.03
50-Day Range
$0.92
$1.08
52-Week Range
$0.86
$3.30
Volume
55,704 shs
Average Volume
128,635 shs
Market Capitalization
$56.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.85

Homology Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
786.1% Upside
$8.73 Price Target
Short Interest
Healthy
0.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.00mentions of Homology Medicines in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$15,899 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.82) to ($1.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

109th out of 983 stocks

Pharmaceutical Preparations Industry

41st out of 486 stocks


FIXX stock logo

About Homology Medicines (NASDAQ:FIXX) Stock

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.

Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

FIXX Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Homology Medicines (FIXX) Gets a Hold from RBC Capital
Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
Credit Suisse Keeps Their Hold Rating on Homology Medicines (FIXX)
BTIG Sticks to Its Buy Rating for Homology Medicines (FIXX)
See More Headlines

FIXX Price History

FIXX Company Calendar

Last Earnings
3/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
224
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$8.73
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$2.10
Forecasted Upside/Downside
+595.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-5,010,000.00
Net Margins
-3,926.25%
Pretax Margin
-3,694.11%

Debt

Sales & Book Value

Annual Sales
$3.21 million
Book Value
$2.63 per share

Miscellaneous

Free Float
44,791,000
Market Cap
$56.92 million
Optionable
Not Optionable
Beta
-0.06

Social Links


Key Executives

  • Albert SeymourAlbert Seymour
    President, Chief Executive Officer & Director
  • W. Bradford SmithW. Bradford Smith
    Treasurer, Chief Financial & Business Officer
  • Julie Jordan
    Chief Medical Officer
  • Michael Blum
    Chief Commercial Officer
  • Deborah Kinch
    Chief Development Officer













FIXX Stock - Frequently Asked Questions

Should I buy or sell Homology Medicines stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FIXX shares.
View FIXX analyst ratings
or view top-rated stocks.

What is Homology Medicines' stock price forecast for 2023?

6 equities research analysts have issued 1 year target prices for Homology Medicines' stock. Their FIXX share price forecasts range from $2.10 to $20.00. On average, they predict the company's stock price to reach $8.73 in the next year. This suggests a possible upside of 786.1% from the stock's current price.
View analysts price targets for FIXX
or view top-rated stocks among Wall Street analysts.

How have FIXX shares performed in 2023?

Homology Medicines' stock was trading at $1.26 on January 1st, 2023. Since then, FIXX shares have decreased by 21.8% and is now trading at $0.9850.
View the best growth stocks for 2023 here
.

Are investors shorting Homology Medicines?

Homology Medicines saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 268,800 shares, a decline of 23.4% from the April 30th total of 351,000 shares. Based on an average daily volume of 154,100 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.6% of the shares of the stock are sold short.
View Homology Medicines' Short Interest
.

When is Homology Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our FIXX earnings forecast
.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Thursday, March, 9th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.09. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.05 million. Homology Medicines had a negative trailing twelve-month return on equity of 64.66% and a negative net margin of 3,926.25%.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.08%), Bank of America Corp DE (0.73%), Renaissance Technologies LLC (0.54%), Connor Clark & Lunn Investment Management Ltd. (0.30%), Dimensional Fund Advisors LP (0.23%) and FMR LLC (0.13%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, Kush Parmar, Michael Lee Blum, Paul Alloway, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends
.

How do I buy shares of Homology Medicines?

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $0.99.

How much money does Homology Medicines make?

Homology Medicines (NASDAQ:FIXX) has a market capitalization of $56.92 million and generates $3.21 million in revenue each year. The company earns $-5,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

How many employees does Homology Medicines have?

The company employs 224 workers across the globe.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The official website for the company is www.homologymedicines.com. The company can be reached via phone at (781) 301-7277.

This page (NASDAQ:FIXX) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -